| Emily Elise Phillips Pereira, | |
|
22 Mott St, Ansonia, CT 06401-1930 | |
| (203) 676-9759 | |
| Not Available |
| Full Name | Emily Elise Phillips Pereira |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 22 Mott St, Ansonia, Connecticut |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346916376 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 005004 (Connecticut) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Emily Elise Phillips Pereira, 22 Mott St, Ansonia, CT 06401-1930 Ph: (203) 676-9759 | Emily Elise Phillips Pereira, 22 Mott St, Ansonia, CT 06401-1930 Ph: (203) 676-9759 |
News Archive
In patients with advanced thyroid cancer, sunitinib, a drug approved for treatment of several other cancers, showed significant cancer-fighting activity t, a new phase 2 clinical trial has found. Results of the single-center study will be presented Sunday at the Endocrine Society's 97th annual meeting in San Diego.
Starvation early in life can alter an organism for generations to come, according to a new study in roundworms. The effects are what Duke University biologist Ryan Baugh terms a "bet-hedging strategy."
Ohio University researchers found medical students may be more confident than knowledgeable when it comes to nutrition. Of the 257 medical students studied, more than 55 percent were confident they could counsel patients on nutritional recommendations, but half did not achieve a passing score on a nutrition quiz, according to a study published in The Journal of the American Osteopathic Association.
The results of an innovative study to understand what factors may influence who contracts tuberculosis (TB)/HIV co-infection in San Diego show a significant shift in the ethnic makeup of the disease, with the majority of cases now coming from the Hispanic community.
Cancer Research Technology, the commercial arm of Cancer Research UK, and Paris-based venture capital firm, Kurma Life Sciences Partners (Kurma), have launched a spin-out company, BliNK Therapeutics Ltd, to generate monoclonal antibodies using a novel platform.
› Verified 6 days ago